Microbot Medical Inc. (MBOT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under ...
Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market ReleaseHINGHAM, Mass., March 10, ...
HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that Harel Gadot, ...
Investing.com - H.C. Wainwright reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ:MBOT) shares following the company’s announcement of hospital adoption in Florida. The stock ...
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its ...
Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries ...
The Company’s designated Notified Body confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results